Adalimumab treatment of resistant chondrocalcinosis
Articles > Article ยท 2024
Authors: Fatih Tastekin, Kenan AKSU
REUMATOLOGIA CLINICA, Journal Indexed in SCI Expanded, International, Scopus, 2024, vol 20, pp 452-453
DOI: 10.1016/j.reuma.2024.06.003
Summary
In this article, we present a case of resistant chondrocalcinosis who had a good response with 40 mg subcutaneous adalimumab. To our knowledge, this is the first report using adalimumab successfully in severe CPDD. Anti-TNF therapy can be a good therapeutic option for second line therapy in CPPD.